研究简介
长期从事人类新发突发呼吸系统传染病致病机制及相关药物治疗方法研究。在研方向包括1）呼吸系统冠状病毒感染特性及致病性研究；2）冠状病毒与宿主细胞死亡通路互作机制研究；3）冠状病毒感染天然免疫应答研究；4）抗病毒药物研发与作用机制研究。在新发病毒研究领域共发表SCI收录论文27篇，H因子19，总引用>3190次。其中以第一和共同第一作者身份在Nature、Nature Microbiology、Signal Transduction and Targeted Therapy和Journal of Infection等国际知名期刊发表SCI研究论文5篇。
荣誉奖励
1. 国家重大人才项目入选者（青年）
代表性成果
1.Chu H#*, Hou Y#, Yang D, Wen L, Shuai H, Yoon C, Shi J, Chai Y, Yuen TT, Hu B, Li C, Zhao X, Wang Y, Huang X, Lee KS, Luo C, Cai JP, Poon VK, Chan CC, Zhang AJ, Yuan S, Sit KY, Foo DC, Au WK, Wong KK, Zhou J, Kok KH, Jin DY, Chan JF*, Yuen KY*. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature. 2022 ;609(7928):785-792.
2. Hou Y#, Li C#, Yoon C#, Leung OW, You S, Cui X, Chan JF, Pei D, Cheung HH*, Chu H*. Enhanced replication of SARS-CoV-2 Omicron BA.2 in human forebrain and midbrain organoids. Signal Transduct Target Ther. 2022 Nov 20;7(1):381.
3. Huang C#, Shuai H#, Qiao J#, Hou Y#, Zeng R#, Xia A#, Xie L#, Fang Z#, Li Y, Yoon C, Huang Q, Hu B, You J, Quan B, Zhao X, Guo N, Zhang S, Ma R, Zhang J, Wang Y, Yang R, Zhang S, Nan J, Xu H, Wang F, Lei J*, Chu H*, Yang S*. A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. Signal Transduct Target Ther. 2023 Mar 16;8(1):128.
4. Quan BX#, Shuai H#, Xia AJ#, Hou Y#, Zeng R#, Liu XL#, Lin GF#, Qiao JX#, Li WP, Wang FL, Wang K, Zhou RJ, Yuen TT, Chen MX, Yoon C, Wu M, Zhang SY, Huang C, Wang YF, Yang W, Tian C, Li WM, Wei YQ, Yuen KY, Chan JF*, Lei J*, Chu H*, Yang S*. An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. Nat Microbiol. 2022 May;7(5):716-725.
